How to access Tecvayli from India — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Indian patient with relapsed or refractory multiple myeloma whose disease has progressed after multiple prior lines of therapy may be evaluated by their treating haematologist for Tecvayli (teclistamab-cqyv). Tecvayli is FDA-approved, developed by Janssen (Johnson & Johnson), and is a BCMA×CD3 bispecific antibody — a "shelf" immunotherapy that engages the patient's own T cells against BCMA-expressing myeloma plasma cells. Unlike CAR-T, Tecvayli does not require autologous cell manufacturing, making it an attractive option where CAR-T infrastructure or timing is not feasible.
This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Tecvayli is administered as a subcutaneous injection on a step-up schedule — small priming doses followed by a target weekly dose — to reduce cytokine release syndrome risk. The step-up doses are typically given in an inpatient or closely monitored setting; subsequent weekly doses transition to outpatient. Eligibility is based on prior line history, fitness for immune-engaging therapy, and access to a haematology unit familiar with CRS and neurotoxicity monitoring. Your haematologist will confirm eligibility, coordinate the step-up admission, and set up ongoing weekly dosing logistics.
Is Tecvayli legally importable into India?
Yes — through the CDSCO / Drugs Controller General of India (DCGI) personal-use and hospital-sponsored named-patient import frameworks. The route permits a registered medical practitioner to request import of a medicine that is not locally registered when the medicine is approved by a recognised reference authority (FDA qualifies), no clinically equivalent registered option is suitable, and chain of custody is documented.
For bispecific antibodies like Tecvayli — a cold-chain biologic administered in an outpatient / short-stay haematology setting after initial step-up — many Indian tertiary centres in Mumbai, Delhi, Bangalore, Chennai, Hyderabad, and Kolkata already have the infrastructure to receive and administer under the named-patient framework. Diaspora families supporting care at home are a common pattern for this class of therapy.
How the pathway works, step by step
- Consultation with your treating haematologist. Eligibility assessment including line history and fitness for bispecific therapy.
- Hospital coordination. The haematology unit confirms step-up admission capacity and CRS/neurotoxicity monitoring protocols.
- CDSCO application. The physician or hospital files the personal-use / named-patient application with clinical rationale, patient identification, and product details.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from authorised distribution.
- Cold-chain shipment. The product ships with continuous temperature monitoring and chain-of-custody documentation end to end.
- Arrival, step-up, and ongoing weekly dosing. The hospital pharmacy receives product and releases doses for the step-up admission and subsequent weekly injections.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming relapsed/refractory myeloma, line history, and Tecvayli as the indicated treatment
- Verification of their Indian medical registration (MCI / NMC)
- Identification of the admitting haematology unit and the CRS/neurotoxicity monitoring plan
- Patient identifier and address for the import record
- Planned step-up schedule and transition to weekly maintenance dosing
Reserve Meds provides a physician documentation kit that bundles the templates Indian customs and CDSCO reviewers expect to see, including the CRS/neurotoxicity surveillance plan that is a standing element for BCMA×CD3 bispecifics.
Costs and timing
Tecvayli's US cash-pay reference price is driven by vial size and weekly dosing frequency. Indicative 2026 cost for a 4-week maintenance supply sits in a broad range of roughly USD 39,000–48,000, with total course cost driven by duration on therapy. The initial step-up cycle typically costs less in drug spend but includes inpatient monitoring costs locally. International cold-chain logistics, customs clearance, CDSCO documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake.
Indicative timing — not guaranteed — for the first step-up dose after cohort intake opens is approximately 14–28 days from the moment a complete application is submitted and customs processing begins. Subsequent weekly doses ship on a rolling basis against your dosing calendar.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
A culturally-aware note: multi-generational Indian families often coordinate myeloma care across cities — a patient in Pune, a haematologist in Mumbai, a son in the US helping with funding. Our concierge case lead is set up to include every designated family member on coordination calls and document flow.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Tecvayli specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for CDSCO / customs review.
- Logistics. Cold-chain, temperature-monitored, internationally tracked shipment coordination.
- Concierge case lead. A named point of contact for the family wherever they are based.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating haematologist. We operate on a waitlist basis during our pre-launch phase.
Frequently asked
Is this legal in India? Yes, when executed through the CDSCO personal-use / named-patient framework with appropriate documentation. Cross-border imports for advanced haematology therapies are a routine mechanism in Indian academic and private tertiary centres. See our trust and compliance page.
Why bispecific rather than CAR-T? Tecvayli is an off-the-shelf product — ready when the patient is ready. CAR-T requires autologous cell manufacturing with a 4–8 week window. For patients who cannot wait or who lack access to CAR-T infrastructure, a BCMA bispecific is often the pragmatic alternative. Your haematologist will explain sequencing.
Can the family abroad pay directly? Yes. Cross-border payment to the US coordinator is common for diaspora-supported care, and we issue invoicing that family members in the US, UK, UAE, Canada, and elsewhere can settle directly.
What about CRS and neurotoxicity monitoring? Your haematology team manages CRS/ICANS monitoring per international protocols, supported by the step-up schedule that is standard for this class.
Will insurance cover this? Cash-pay is the default. Some Indian private insurers and diaspora policies consider named-patient imports case by case; we supply documentation for your submission but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Tecvayli coordination in India.
Add me to the Tecvayli waitlistComposite case examples. Reserve Meds is in pre-launch. This content is for general information and does not constitute medical advice.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.